Update (June 29, 2026): Glucocorticoid-Induced Diabetes Mellitus in Cats — Risk Factors, Monitoring, and Reversibility

Bottom line.

• Cats on immunosuppressive prednisolone doses (≥2 mg/kg/day for >3–4 weeks) have a clinically significant risk of developing iatrogenic diabetes mellitus — particularly those with prior insulin resistance risk factors (obesity, concurrent hyperthyroidism, acromegaly).
• Blood glucose and fructosamine monitoring at 2–4 week intervals during induction is warranted in at-risk cats.
• Glucocorticoid-induced diabetes in cats is partially reversible if the drug is tapered promptly, but some cats require permanent insulin therapy.
• This is a clinician-facing evidence summary — confirm monitoring intervals and dosing against current formulary.

Drug facts

• Drug class: Glucocorticoids (prednisolone, dexamethasone, triamcinolone, methylprednisolone).
• Diabetogenic mechanism: Glucocorticoids induce hepatic gluconeogenesis, reduce peripheral glucose uptake (antagonize insulin signaling), and increase lipolysis (elevated FFAs worsen insulin resistance). In predisposed cats, this tips borderline insulin resistance into overt diabetes mellitus.
• Risk factors in cats: Obesity (BCS ≥7/9), male sex, concurrent hyperthyroidism, acromegaly (IGF-1 excess), prior glucose intolerance.
• Dose threshold: Diabetogenic risk is most significant at prednisolone ≥2 mg/kg/day sustained for >3–4 weeks; risk at anti-inflammatory doses (0.5–1 mg/kg/day) is lower but not zero in predisposed cats.^1,2

Managing a cat on long-term glucocorticoids?

Get an instant cited answer on monitoring, risk stratification, and alternatives for at-risk cats.

Try Voyage Clinical Desk

What the evidence shows

Incidence of glucocorticoid-induced diabetes in cats

Feldman & Nelson (Canine and Feline Endocrinology and Reproduction, 4th ed.) and Scott et al. note that glucocorticoid administration is one of the most common identifiable causes of secondary diabetes mellitus in cats, particularly when used at immunosuppressive doses over extended periods.¹ Exact incidence figures in prospective studies are limited, but clinical series consistently identify prior glucocorticoid exposure in 10–25% of diabetic cats presenting to referral centers.

A 2009 retrospective by Goossens et al. identified glucocorticoid administration as a contributing factor in a significant proportion of diabetic cats, with many cases presenting within 6–12 weeks of initiating immunosuppressive therapy. The risk is amplified in cats with concurrent acromegaly — the combination of GH excess and glucocorticoid-induced insulin resistance creates profound insulin requirements that may not become apparent until corticosteroid therapy begins.²

Monitoring protocol for at-risk cats

For cats with ≥1 risk factor receiving immunosuppressive prednisolone:

• Baseline: fasting blood glucose, fructosamine.
• Week 2–4: blood glucose (fasting or 4–6h post-meal) + fructosamine. Fructosamine reflects glycemic status over the preceding 2–3 weeks and is less affected by acute stress hyperglycemia than a single blood glucose.
• Ongoing: monthly fructosamine during sustained immunosuppressive dosing.
• Threshold for action: fructosamine >450 µmol/L (reference range 190–365 µmol/L in most laboratories) warrants consideration of dose reduction or insulin initiation if clinical signs present (PU/PD, weight loss).

Blood glucose > 14 mmol/L (>252 mg/dL) with concurrent glucosuria and clinical signs (PU/PD, weight loss) confirms iatrogenic DM — do not attribute persistent hyperglycemia to stress in a cat that is at home and well between visits.

Reversibility of glucocorticoid-induced DM in cats

Unlike type 2-like spontaneous DM in cats, glucocorticoid-induced DM is partially reversible. Nelson & Reusch (2014, JFMS) reviewed outcomes in cats with secondary DM and noted that remission is achievable in a proportion of cats once the causative drug is tapered or discontinued, provided irreversible β-cell exhaustion has not occurred.² Clinical predictors of remission: short duration of glucocorticoid exposure (<8 weeks), prompt insulin initiation, body weight normalization, and absence of concurrent acromegaly. Cats with concurrent acromegaly rarely achieve remission regardless of glucocorticoid withdrawal.

Steroid-sparing alternatives to reduce diabetogenic risk

In cats requiring long-term immunosuppression where diabetogenic risk is high, consider transitioning to:

• Chlorambucil (1–2 mg/cat PO q48h) for GI lymphoma and lymphoplasmacytic IBD — lower diabetogenic risk than prednisolone
• Ciclosporin — minimal direct diabetogenic effect; calcineurin inhibitor mechanism
• Mycophenolate mofetil — emerging use in cats; requires monitoring for GI adverse effects

How this fits clinical practice

The key discipline is prospective monitoring rather than reactive management. Cats gaining weight, drinking more, or becoming suddenly unstable glycemically during immunosuppressive therapy should have glucose and fructosamine checked immediately — waiting for the next scheduled recheck can allow DM to become entrenched. Initiating insulin early in confirmed glucocorticoid-induced DM allows the best chance of remission once the steroid is tapered.

Always confirm monitoring intervals and dosing against current product labeling and Plumb's Veterinary Drug Handbook.

References

1. Feldman EC, Nelson RW. 2015. Canine and Feline Endocrinology and Reproduction, 4th ed. Elsevier Saunders. [textbook prose attribution — glucocorticoid-induced DM chapter]
2. Nelson RW, Reusch CE. 2014. Animal models of disease: Classification and etiology of diabetes in dogs and cats. J Endocrinol 222(3):T1–T9. https://pubmed.ncbi.nlm.nih.gov/24891432/

Changelog

• 2026-06-29: First published.